Drugs / SSGJ-612
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07032298 | Jul 2025 → Apr 2026 overdue | cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07646626 | Jul 2026 → Jun 2027 expected | cancer of unknown primary site | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSGJ-612 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07646626 ↗ |
| Route | Intravenous | “Intravenous injection” NCT07032298 ↗ |